{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:02:59Z","timestamp":1790269379462,"version":"4.1.0"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.2169\/internalmedicine.1359-18","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T18:36:54Z","timestamp":1535049414000},"page":"361-368","source":"Crossref","is-referenced-by-count":70,"title":["Antidepressants for Depression, Apathy, and Gait Instability in Parkinson's Disease: A Multicenter Randomized Study"],"prefix":"10.2169","volume":"58","author":[{"given":"Makio","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Neurology, Osaka Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Tabu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kitano Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Osaka Saiseikai Nakatsu Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Hamano","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kansai Electric Power Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Takeshima","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tominaga Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the REBORN study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ellis T, Cavanaugh JT, Earhart GM, Ford MP, Foreman KB, Dibble LE. Which measures of physical function and motor impairment best predict quality of life in Parkinson's disease? Parkinsonism Relat Disord 17: 693-697, 2011.","DOI":"10.1016\/j.parkreldis.2011.07.004"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 69: 308-312, 2000.","DOI":"10.1136\/jnnp.69.3.308"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 23: 183-189, 2008.","DOI":"10.1002\/mds.21803"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th Ed). American Psychiatric Association, Washington, DC, 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nagayama H, Maeda T, Uchiyama T, et al. Anhedonia and its correlation with clinical aspects in Parkinson's disease. J Neurol Sci 372: 403-407, 2017.","DOI":"10.1016\/j.jns.2016.10.051"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kelberman MA, Vazey EM. New pharmacological approaches to treating non-motor symptoms of Parkinson's disease. Curr Pharmacol Rep 2: 253-261, 2016.","DOI":"10.1007\/s40495-016-0071-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Liu J, Dong J, Wang L, Su Y, Yan P, Sun S. Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis. PLoS ONE 8: e76651, 2013.","DOI":"10.1371\/journal.pone.0076651"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Rocha FL, Murad MG, Stumpf BP, Hara C, Fuzikawa C. Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis. J Psychopharmacol 27: 417-423, 2013.","DOI":"10.1177\/0269881113478282"},{"key":"9","doi-asserted-by":"crossref","first-page":"e79510","DOI":"10.1371\/journal.pone.0079510","volume":"8","author":"L Troeung","year":"2013","unstructured":"9. Troeung L, Egan SJ, Gasson N. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease. PLoS ONE 8: e79510, 2013.","journal-title":"PLoS ONE","ISSN":"https:\/\/id.crossref.org\/issn\/1932-6203","issn-type":"print"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE. Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA. Acta Neurol Scand 62: 210-219, 1980.","DOI":"10.1111\/j.1600-0404.1980.tb03028.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Zahodne LB, Bernal-Pacheco O, Bowers D, et al. Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson's disease? J Neuropsychiatry Clin Neurosci 24: 326-330, 2012.","DOI":"10.1176\/appi.neuropsych.11090210"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Bonuccelli U, Meco G, Fabbrini G, et al. A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. Expert Opin Pharmacother 13: 2269-2280, 2012.","DOI":"10.1517\/14656566.2012.736490"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nishijima H, Ueno T, Kon T, et al. Effects of duloxetine on motor and mood symptoms in Parkinson's disease: an open-label clinical experience. J Neurol Sci 375: 186-189, 2017.","DOI":"10.1016\/j.jns.2017.01.066"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 78: 1229-1236, 2012.","DOI":"10.1212\/WNL.0b013e3182516244"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Morgante F, Fasano A. Improvement with duloxetine in primary progressive freezing gait. Neurology 75: 2130-2132, 2010.","DOI":"10.1212\/WNL.0b013e318200d7a3"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Giladi N. Medical treatment of freezing of gait. Mov Disord 23: S482-S488, 2008.","DOI":"10.1002\/mds.21914"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kihara T, Ikeda M. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther 272: 177-183, 1995.","DOI":"10.1016\/S0022-3565(25)24303-8"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 4: 134-139, 1992.","DOI":"10.1176\/jnp.4.2.134"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Giladi N, Tal J, Azulay T, et al. Validation of the freezing of gait questionnaire in patients with Parkinson's disease. Mov Disord 24: 655-661, 2009.","DOI":"10.1002\/mds.21745"},{"key":"20","unstructured":"20. Busner J, Targum SD. The Clinical Global Impressions Scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 4: 28-37, 2007."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Akca A, Mehmet AK, Sutcugil L, Ozsahin A, Kutukcu Y. Comparison of sertraline and venlafaxine treatments for depression in Parkinson's disease. Noropsikiyatri Arsivi (Archives of Neuropsychiatry) 48: 201-206, 2011.","DOI":"10.4274\/Npa.Y5711"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton Depression Rating Scale. J Affect Disord 150: 384-388, 2013.","DOI":"10.1016\/j.jad.2013.04.028"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Bomasang-Layno E, Fadlon I, Murray AN, Himelhoch S. Antidepressive treatments for Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 21: 833-842, 2015.","DOI":"10.1016\/j.parkreldis.2015.04.018"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Zhuo C, Xue R, Luo L, et al. Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis. Medicine 96: e6698, 2017.","DOI":"10.1097\/MD.0000000000006698"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 75: 448-455, 2010.","DOI":"10.1212\/WNL.0b013e3181ebdd79"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ding YS, Naganawa M, Gallezot JD, et al. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: implications on treatment of depression and ADHD. NeuroImage 86: 164-171, 2014.","DOI":"10.1016\/j.neuroimage.2013.08.001"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol 50: 873-880, 1993.","DOI":"10.1001\/archneur.1993.00540080076020"},{"key":"28","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1212\/WNL.56.12.1712","volume":"56","author":"N Giladi","year":"2001","unstructured":"28. Giladi N, McDermott MP, Fahn S, et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 56: 1712-1721, 2001.","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 3: 22-27, 2001.","DOI":"10.4088\/PCC.v03n0105"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Moret C, Isaac M, Briley M. Review: problems associated with long-term treatment with selective serotonin reuptake inhibitors. J Psychopharmacol 23: 967-974, 2008.","DOI":"10.1177\/0269881108093582"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/3\/58_1359-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T10:20:38Z","timestamp":1751797238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/3\/58_1359-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1359-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,1]]}}}